• 1. An atom-economical protocol for direct conversion of Baylis–Hillman alcohols to β-chloro aldehydes in water?
  Raktani Bikshapathi,Sai Prathima Parvathaneni,Vaidya Jayathirtha Rao Green Chem., 2017,19, 4446-4450
• 2. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 3. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388
• 4. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 5. An artificial blood vessel implanted three-dimensional microsystem for modeling transvascular migration of tumor cells?
  Xue-Ying Wang,Ying Pei,Min Xie,Zi-He Jin,Ya-Shi Xiao,Yang Wang,Li-Na Zhang,Yan Li,Wei-Hua Huang Lab Chip, 2015,15, 1178-1187

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolopyridines Pyrrolopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolopyridines

Introduction to 1,5-dihydro-6-methyl-4H-Pyrrolo[3,2-c]pyridin-4-one (CAS No. 178268-91-2) and Its Emerging Applications in Chemical Biology

The compound 1,5-dihydro-6-methyl-4H-Pyrrolo[3,2-c]pyridin-4-one (CAS No. 178268-91-2) represents a structurally intriguing heterocyclic scaffold that has garnered significant attention in the field of chemical biology and drug discovery. Its unique pyrrolopyridine core, characterized by a fused ring system of a pyrrole and a pyridine moiety, positions it as a versatile building block for the development of novel pharmacological agents. The presence of a methyl substituent at the 6-position and a carbonyl group at the 4-position further enhances its synthetic appeal, enabling diverse functionalization strategies.

Recent advancements in medicinal chemistry have highlighted the potential of this compound as a precursor for small-molecule inhibitors targeting various biological pathways. The pyrrolopyridine scaffold is known for its ability to interact with biological macromolecules through multiple hydrogen bonding interactions and hydrophobic pockets, making it an ideal candidate for designing high-affinity ligands. For instance, studies have demonstrated its utility in developing kinase inhibitors, where the rigid fused ring system provides structural stability while the electron-rich nitrogen atoms facilitate coordination with target proteins.

One of the most compelling aspects of 1,5-dihydro-6-methyl-4H-Pyrrolo[3,2-c]pyridin-4-one is its versatility in derivative synthesis. Researchers have leveraged its reactive sites to introduce diverse substituents, leading to a library of analogs with tailored biological activities. Notably, modifications at the 3-position of the pyrrole ring have been explored for enhancing binding affinity to specific enzyme targets. These derivatives exhibit promising preclinical profiles in models of inflammation and cancer, underscoring their therapeutic potential.

The synthesis of 1,5-dihydro-6-methyl-4H-Pyrrolo[3,2-c]pyridin-4-one itself presents an interesting challenge due to the complexity of the fused heterocyclic system. Traditional approaches involve multi-step sequences involving cyclization reactions and functional group transformations. However, recent methodologies have focused on more efficient synthetic routes, such as transition-metal-catalyzed cross-coupling reactions and microwave-assisted organic synthesis (MAOS), which significantly reduce reaction times and improve yields. These innovations are crucial for scaling up production while maintaining cost-effectiveness.

In the realm of computational chemistry, 1,5-dihydro-6-methyl-4H-Pyrrolo[3,2-c]pyridin-4-one has been extensively studied to elucidate its molecular interactions. Molecular docking simulations have revealed that this compound can effectively bind to ATP-binding pockets in kinases, suggesting its potential as an allosteric modulator. Such insights are invaluable for rational drug design, allowing chemists to optimize lead structures before experimental validation. Additionally, quantum mechanical calculations have provided detailed insights into its electronic structure and reactivity, guiding synthetic modifications.

The pharmacokinetic properties of derivatives derived from 1,5-dihydro-6-methyl-4H-Pyrrolo[3,2-c]pyridin-4-one are another area of active investigation. Structural modifications aimed at improving solubility and metabolic stability have been crucial for advancing candidates into clinical trials. For example, incorporating polar functional groups such as carboxylic acids or amides has been shown to enhance oral bioavailability while minimizing off-target effects. These efforts align with current trends in drug development toward achieving optimal pharmacokinetic profiles.

Emerging research also highlights the role of 1,5-dihydro-6-methyl-4H-Pyrrolo[3,2-c]pyridin-4-one in modulating neurobiological pathways. Preliminary studies suggest that certain derivatives exhibit neuroprotective effects by inhibiting oxidative stress-induced neuronal damage. This opens up new avenues for treating neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease. The ability of these compounds to cross the blood-brain barrier remains a key focus area for further investigation.

The environmental impact of synthesizing 1,5-dihydro-6-methyl-4H-Pyrrolo[3,2-c]pyridin-4-one and its derivatives has also been addressed in recent literature. Green chemistry principles have been applied to develop more sustainable synthetic methodologies that minimize waste generation and hazardous solvent use. For instance, biocatalytic approaches employing engineered enzymes have shown promise in facilitating key transformations under mild conditions. Such innovations are essential for ensuring that drug development remains environmentally responsible.

Future directions in the study of 1,5-dihydro-6-methyl-4H-Pyrrolo[3,2-c]pyridin-4-one include exploring its role in modulating immune responses. Preliminary data indicate that certain analogs can influence cytokine production by interacting with immune cell receptors. This could pave the way for novel immunomodulatory therapies targeting autoimmune diseases or cancer immunotherapy. The integration of machine learning algorithms into virtual screening campaigns is also expected to accelerate the discovery process by identifying promising derivatives with minimal experimental screening.

In conclusion,1 ,5 -dihydro -6 -methyl -4 H -Pyrrolo [ 3 , 2 -c ] pyridin - 4 -one (CAS No . 178268 -91 - 2 ) stands out as a structurally versatile scaffold with significant therapeutic potential across multiple disease areas . Its unique chemical properties , coupled with advances in synthetic methodologies and computational modeling , position it as a cornerstone compound in modern medicinal chemistry . As research continues to uncover new applications , this heterocyclic scaffold is poised to make substantial contributions to human health and well-being .

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)